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The authors thank Yamakazi et al for their interest in our article
and for raising several interesting and relevant questions regarding
our findings.
We agree that it is possible a lower total biological effective
dose (BED) was responsible for the lower biochemical progres-
sion free survival (PFS) observed for patients treated with high
dose rate brachytherapy (HDR) boost especially for the 17Gy
in 2 fractions schedule. An indication of this might be that only
8.7% of patients treated with HDR boost achieved a nadir PSA<
0.1ng/ml compared with 44.8% of patients treated with low dose
rate brachytherapy (LDR) boost. However, we do also note inher-
ent uncertainties/assumptions in comparing BED between LDR
and HDR brachytherapy/external beam radiotherapy (EBRT)
schedules.
50 patients treated with HDR boost received 17Gy in 2 fractions
and 121 patients received 15Gy in 1 fraction. The majority of
patients in both HDR and LDR boost cohorts with T3 disease had
T3a disease. In the HDR boost group, 77 had T3a disease, 19 had
T3b disease and 1 patient was classified as T3 not otherwise spec-
ified. In the LDR boost group, 50 patients had T3a disease, 5 had
T3b disease and 1 patient T3 not otherwise specified. Given the
small numbers in these subgroups and the risk of a type 1 error/-
false positive result, we do not intend to undertake multiple com-
parisons of bPFS between the two HDR boost schedules,
intermediate and high risk disease and T3a versus T3b disease.
We accept the small discrepancy between the numbers of patients
with T3a/b disease and those classified as having high risk disease
in Table 1.
We accept that the median follow up for the HDR boost group
was shorter than for the LDR group because the HDR boost tech-
nique was implemented more recently but we suggest that the
number of relapses in the HDR boost group was still higher than
would be expected with relatively short follow up and the majority
of patients treated with hormone therapy.
We agree with Yamakazi et al that further investigation of the
optimum dose/fractionation schedule for EBRT plus HDR boost
within a robust clinical trial is important.uropean Socie
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